Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1278391

Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries


Rotar, Alexandru M.; Preda, Alin; Löblová, Olga; Benkovic, Vanesa; Zawodnik, Szymon; Gulacsi, Laszlo; Niewada, Maciej; Boncz, Imre; Petrova, Guenka; Dimitrova, Maria; Klazinga, Niek
Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries // Health policy, 122 (2018), 3; 230-236 doi:10.1016/j.healthpol.2018.01.006 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1278391 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries

Autori
Rotar, Alexandru M. ; Preda, Alin ; Löblová, Olga ; Benkovic, Vanesa ; Zawodnik, Szymon ; Gulacsi, Laszlo ; Niewada, Maciej ; Boncz, Imre ; Petrova, Guenka ; Dimitrova, Maria ; Klazinga, Niek

Izvornik
Health policy (0168-8510) 122 (2018), 3; 230-236

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
managed entry agreements, costs, Central and Eastern European countries,

Sažetak
This paper aims to provide an overview of the rationalization strategies for the introduction and use of pharmaceuticals, focusing on the role of managed entry agreements (MEA) in Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Croatia, Hungary, Poland and Romania. We developed a conceptual framework on MEAs that was used as the basis for a standardized assessment questionnaire sent to country experts to capture their perceptions on their countries’ rationalization strategies and MEAs. Our study shows that the main role of MEAs and other related policies embedded in the health care system is to limit the budget impact of drugs in all examined 6 countries. Uncertainty about outcomes and appropriate utilization seem to be of lower priority. Finance-based MEAs are used by all countries. Performance-based MEAs are scarce and used to a limited extent by Hungary and Poland. The overall transparency of the existence and details of MEAs is limited. Expansion of the use and increased transparency of MEAs is recommended. Still, the informational infrastructure and competencies in implementing MEA’s need to be developed further.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita, Ekonomija, Interdisciplinarne društvene znanosti



POVEZANOST RADA


Profili:

Avatar Url Vanesa Benković (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com

Citiraj ovu publikaciju:

Rotar, Alexandru M.; Preda, Alin; Löblová, Olga; Benkovic, Vanesa; Zawodnik, Szymon; Gulacsi, Laszlo; Niewada, Maciej; Boncz, Imre; Petrova, Guenka; Dimitrova, Maria; Klazinga, Niek
Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries // Health policy, 122 (2018), 3; 230-236 doi:10.1016/j.healthpol.2018.01.006 (međunarodna recenzija, članak, znanstveni)
Rotar, A., Preda, A., Löblová, O., Benkovic, V., Zawodnik, S., Gulacsi, L., Niewada, M., Boncz, I., Petrova, G., Dimitrova, M. & Klazinga, N. (2018) Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. Health policy, 122 (3), 230-236 doi:10.1016/j.healthpol.2018.01.006.
@article{article, author = {Rotar, Alexandru M. and Preda, Alin and L\"{o}blov\'{a}, Olga and Benkovic, Vanesa and Zawodnik, Szymon and Gulacsi, Laszlo and Niewada, Maciej and Boncz, Imre and Petrova, Guenka and Dimitrova, Maria and Klazinga, Niek}, year = {2018}, pages = {230-236}, DOI = {10.1016/j.healthpol.2018.01.006}, keywords = {managed entry agreements, costs, Central and Eastern European countries,}, journal = {Health policy}, doi = {10.1016/j.healthpol.2018.01.006}, volume = {122}, number = {3}, issn = {0168-8510}, title = {Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries}, keyword = {managed entry agreements, costs, Central and Eastern European countries,} }
@article{article, author = {Rotar, Alexandru M. and Preda, Alin and L\"{o}blov\'{a}, Olga and Benkovic, Vanesa and Zawodnik, Szymon and Gulacsi, Laszlo and Niewada, Maciej and Boncz, Imre and Petrova, Guenka and Dimitrova, Maria and Klazinga, Niek}, year = {2018}, pages = {230-236}, DOI = {10.1016/j.healthpol.2018.01.006}, keywords = {managed entry agreements, costs, Central and Eastern European countries,}, journal = {Health policy}, doi = {10.1016/j.healthpol.2018.01.006}, volume = {122}, number = {3}, issn = {0168-8510}, title = {Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries}, keyword = {managed entry agreements, costs, Central and Eastern European countries,} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font